Article

4'-epi-doxorubicin in combination with cisplatin in advanced ovarian cancer.

Cancer treatment reports 12/1984; 68(11):1391-3. pp.1391-3
Source: PubMed

ABSTRACT Thirty-two patients with advanced ovarian cancer were treated with a combination of 4'-epi-doxorubicin, a new analog of doxorubicin, and cisplatin at a dose of 60 and 50 mg/m2, respectively, every 28 days. Twelve patients had previously received chemotherapy and/or radiotherapy. Of 29 evaluable patients, six (21%) achieved complete remission for a median duration of 19+ months, and 13 (45%) achieved partial remission for a median duration of 8 months. All complete remissions were confirmed by a "second-look" procedure. Main side effects included vomiting in all patients, moderate myelosuppression (67%), and alopecia (65%). No case of congestive heart failure was observed. 4'-Epi-doxorubicin plus cisplatin is an effective and relatively well-tolerated regimen in the treatment of advanced ovarian cancer.

0 0
 · 
0 Bookmarks
 · 
13 Views
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

29 evaluable patients
 
8 months
 
chemotherapy
 
complete remission
 
complete remissions
 
congestive heart failure
 
Main side effects
 
median duration
 
moderate myelosuppression
 
new analog
 
partial remission
 
patients
 

A Martoni